The American Journal of Medicine
Volume 120, Issue 9 , Pages 783-790 , September 2007

Efficacy of Short-Course Antibiotic Regimens for Community-Acquired Pneumonia: A Meta-analysis

The data in this article were presented in part at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006 (Session 162, Paper L-1458).

  • Jonathan Z. Li, MD

      Affiliations

    • Department of Medicine, San Francisco VA Medical Center, University of California, San Francisco.
    • Corresponding Author InformationRequests for reprints should be addressed to Jonathan Z. Li, MD, Department of Medicine, University of California, San Francisco, Box 0862, 5H22, San Francisco, CA 94143-0862.
    • ,
  • Lisa G. Winston, MD

      Affiliations

    • Department of Medicine, San Francisco VA Medical Center, University of California, San Francisco.
    • Infectious Diseases Division, San Francisco VA Medical Center, University of California, San Francisco.
    • ,
  • Dan H. Moore, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, San Francisco VA Medical Center, University of California, San Francisco.
    • ,
  • Stephen Bent, MD

      Affiliations

    • General Internal Medicine Section, San Francisco VA Medical Center, University of California, San Francisco.

References 

  1. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults (Infectious Diseases Society of America). Clin Infect Dis. 2000;31(2):347–382
  2. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18(4):761–776Dec, vii
  3. File TM, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest. 2004;125(5):1888–1901
  4. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med. 2005;118(7 Suppl):21S–28S
  5. File TM. Community-acquired pneumonia. Lancet. 2003;362(9400):1991–2001
  6. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005;330(7489):456
  7. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia (Diagnosis, assessment of severity, antimicrobial therapy, and prevention). Am J Respir Crit Care Med. 2001;163(7):1730–1754
  8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72
  9. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37(11):1405–1433
  10. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31(2):383–421
  11. Halm EA, Teirstein AS. Clinical practice (Management of community-acquired pneumonia). N Engl J Med. 2002;347(25):2039–2045
  12. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2004;2:CD002109
  13. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005;165(17):1992–2000
  14. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):IV1–IV64
  15. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother. 2001;48(5):691–703
  16. File TM. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis. 2004;39(Suppl 3):S159–S164
  17. Hopkins S, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Curr Ther Res Clin Exp. 1995;56(9):915–925
  18. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother. 1998;10(1):64–68
  19. Mandell LA, File TM. Short-course treatment of community-acquired pneumonia. Clin Infect Dis. 2003;37(6):761–763
  20. Kolditz M, Halank M, Hoffken G. Short-course antimicrobial therapy for community-acquired pneumonia. Treat Respir Med. 2005;4(4):231–239
  21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  22. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250
  23. Bohte R, Van’t Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1995;14(3):182–187
  24. Brion JP, Sedallian A, Le Noc P, et al. Azithromycin versus josamycin: treatment of 89 acute pneumonia cases. Pathol Biol (Paris). 1990;38(5 Pt 2):521–525
  25. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10(10):872–877
  26. Kobayashi H, Sakayori S, Koike T, et al. Clarithromycin-controlled randomized double-blind studies of azithromycin for treatment of pneumonia. Jpn J Chemother. 1995;43(8):757–774
  27. O’Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1998;17(12):828–833
  28. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents. 2004;24(2):181–184
  29. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J. 1995;8(3):398–402
  30. Schonwald S, Barsic B, Klinar I, Gunjaca M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis. 1994;26(6):706–710
  31. Schonwald S, Gunjaca M, Kolacny-Babic L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother. 1990;25(Suppl A):123–126
  32. Sopena N, Martinez-Vazquez C, Rodriguez-Suarez JR, et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother. 2004;16(1):102–103
  33. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis. 2003;37(6):752–760
  34. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004;98(8):708–720
  35. Leophonte P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect. 2002;32(7):369–381
  36. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther. 1999;6(4):217–222
  37. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004;54(2):515–523
  38. File TM, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18(4):993–1016
  39. Restrepo MI, Anzueto A. Antimicrobial treatment of community-acquired pneumonia. Clin Chest Med. 2005;26(1):65–73
  40. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet. 2002;360(9336):835–841
  41. Agarwal G, Awasthi S, Kabra SK, et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ. 2004;328(7443):791
  42. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol. 1979;73(3):235–240
  43. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588–2598
  44. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993;147(1):38–44
  45. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73–82
  46. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355
  47. Richter SS, Heilmann KP, Beekmann SE, et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005;40(2):225–235
  48. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US—an update. Clin Infect Dis. 2004;39(Suppl 3):S142–S150
  49. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis. 2001;33(Suppl 3):S187–S192
  50. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001;286(1):49–56
  51. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49(6):897–903
  52. Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol. 1997;50(11):1297–1304
  53. Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med Clin North Am. 2006;90(6):1165–1182
  54. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003;36(8):963–970
  55. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346(10):747–750
  56. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343(26 I):1917–1924
  57. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother. 2004;48(9):3305–3311
  58. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144(6):415–420
  59. Ross D. The FDA and the case of Ketek. N Engl J Med. 2007;356(16):1601–1604

PII: S0002-9343(07)00554-2

doi: 10.1016/j.amjmed.2007.04.023

The American Journal of Medicine
Volume 120, Issue 9 , Pages 783-790 , September 2007

Article Tools

* Image Usage & Resolution